Trial Profile
Phase II Study of MP-424 in Patients With (Genotype 1b) Hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 04 Sep 2009 Actual patient number (15) added as reported by ClinicalTrials.gov.
- 04 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Sep 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.